■接受射频导管消融(RFCA)的房颤(AF)患者需要服用抗心律失常药物以防止早期复发。这些患者的临床结果可能受到不同的抗心律失常方案的影响。
■确定与早期复发相关的危险因素,并比较不同抗心律失常方案在射频导管消融术(RFCA)后3个月的老年房颤患者中的临床结果。
■一项回顾性观察性研究包括420例RFCA后房颤的老年患者。在最初的术后访视期间收集基线数据,并在3个月的随访期内仔细监测临床结果。进行了Logistic回归和Cox比例风险回归分析,以研究各种抗心律失常方案与临床结局之间的关系。
■多因素logistic回归分析显示,年龄(p=0.001),左心房直径(p<0.001),左心室直径(p=0.015),反应性充血指数(RHI)(p<0.001),抗心律失常药物(p<0.001)和hs-cTnI(p=0.017)是早期复发的独立危险因素。此外,在COX生存回归分析模型中,胺碘酮组早期复发生存率高于普罗帕酮组(HR2.30,95CI1.17-4.53,p=0.016)和索他洛尔组(HR3.60,95CI2.17-5.95,p<0.001).与胺碘酮组相比,决奈达隆组(p=0.046)和普罗帕酮组(p=0.021)肝功能异常的发生率较低.缓慢性心律失常的发生率(p=0.003),索他洛尔组的QT间期延长(p=0.035)和房室传导阻滞(p=0.021)高于胺碘酮组。
■RHI是老年房颤患者RFCA术后早期复发的独立危险因素。与胺碘酮相比,普罗帕酮和索他洛尔的早期复发风险升高.尽管胺碘酮和决奈达隆在早期复发方面没有显着差异,决奈达隆因其药物不良反应发生率低于胺碘酮而成为首选药物.
UNASSIGNED: Patients with atrial fibrillation (AF) who undergo radiofrequency catheter ablation (RFCA) necessitate the administration of antiarrhythmic drugs to prevent early recurrence. The clinical outcomes among these patients may be influenced by varying antiarrhythmic regimens.
UNASSIGNED: To identify the risk factors associated with early recurrence and compare the clinical outcomes among different antiarrhythmic regimens in elderly patients with AF following radiofrequency catheter ablation (RFCA) during a 3-month period.
UNASSIGNED: A retrospective observational study encompassed 420 elderly patients with AF following RFCA. Baseline data were collected during the initial postoperative visit and clinical outcomes were carefully monitored over a 3-month follow-up period. Logistic regression and Cox-proportional hazard regression analyses were performed to investigate the relationship between various antiarrhythmic regimens and the clinical outcomes.
UNASSIGNED: Multivariate logistic regression analysis revealed that age (p = 0.001), left atrial diameter (p < 0.001), left ventricular diameter (p = 0.015), reactive hyperemia index (RHI) (p < 0.001), antiarrhythmic drug (p < 0.001) and hs-cTnI (p = 0.017) were independent risk factors of early recurrence. Furthermore, in cox survival regression analysis model, survival rate of early recurrence in the amiodarone group was higher than in the propafenone group (HR 2.30, 95%CI 1.17-4.53, p = 0.016) and in the sotalol group (HR 3.60, 95%CI 2.17-5.95, p < 0.001). Compared to the amiodarone group, the incidence of liver dysfunction was lower in the dronedarone group (p = 0.046) and the propafenone group (p = 0.021). The incidence of bradyarrhythmia (p = 0.003), QT interval prolongation (p = 0.035) and atrioventricular transmission block (p = 0.021) were higher in the sotalol group than in the amiodarone group.
UNASSIGNED: RHI was identified as an independent risk factor for early recurrence among elderly AF patients after RFCA. Compared to amiodarone, propafenone and sotalol exhibited an elevated risk of early recurrence. Although there was no significant difference in early recurrence between amiodarone and dronedarone, dronedarone emerged as the preferred option due to its lower frequency of adverse drug reactions than amiodarone.